Mark L. Lupher, Jr.;Shawn Li;Teresa K. Surowy; Jr.;Mark L. Lupher;Michael Scott Kramer;David Paul Hesson
发明人:
Mark L. Lupher, Jr.,Teresa K. Surowy,Shawn Li,David Paul Hesson,Michael Scott Kramer
申请号：
US12215700
公开号：
US09884899B2
申请日:
2008.06.27
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The application provides methods for determining a patient's risk for developing fibrosis or a fibrosis-related disorder. Concentrations of C reactive protein (CRP) and serum amyloid protein (SAP) are measured from a biological sample to determine the SAP-to-CRP ratio. This ratio can then be compared with one or more SAP-to-CRP reference ratios to determine a patient's risk for developing a fibrosis related disorder. The diagnostic methods can also be used to determine the severity of fibrosis in a patient afflicted with such a disease. Furthermore, methods for treating patients having a fibrosis-related disorder are provided. For example, a patient that has a lower SAP-to-CRP ratio than one or more reference values may be treated with an SAP agonist and/or CRP antagonist to treat or prevent a fibrosis disorder. The methods may further comprise determining the R131/H131 polymorphism of FcγRIIA as a risk factor for developing fibrosis or a fibrosis-related disorder.
